Merck Props the Dow Up
The Dow Jones Industrial Average is down slightly after finishing higher for the past six trading sessions. As of 1:15 p.m. EDT the Dowis down nine points, or 0.06%, to 14,436. The S&P 500 is down 0.26% to 1,552.
There were two economic releases this morning.
NFIB Small Business Economic Trends
The one to pay attention to is the Department of Labor's job openings report, which showed that job openings edged up in January by 80,000. Hiring and turnover were unchanged from December at respective rates of 3.1% and 3%. The jobs market is a key factor for the U.S. economy, and it has been holding back the domestic recovery as the unemployment rate stays high. Rising job openings show a healthier economy as companies look for more employees.
The report also showed 2.2 million quits -- the highest level since 2008. The level of quits is seen as a barometer for employees' confidence in their ability to find another job and, thus, their confidence in the economy. The level of quits has risen rather steadily since 2009.
Today's Dow leader
Today's Dow leader is Merck , up 3.3%. Earlier today, a medical advisory panel said a large trial for Vytorin can continue. Vytorin is a cholesterol-limiting drug that, along with Zetia, provided the first real competition for Pfizer's Lipitor. The trial includes 18,000 participants, was started in 2005, and is scheduled to end in September 2014.
Merck is trying to show conclusively that Vytorin is significantly more effective than Zocor, another Merck drug that is now available in generic form. Vytorin currently has sales of about $1.75 billion per year, down from 2008, when two smaller studies raised doubts over Vytorin. The first study showed that Vytorin led to an increased risk of cancer, while the second study showed that Vytorin was no more effective than generic Zocor. The continuation of the study is good news for Merck, as it shows that the panel believes the study has a good chance at a positive result. A successful Vytorin trial would be a boon for Merck going forward, but we won't know the result until next September.
Can Merck beat the patent cliff?
This titan of the pharmaceutical industry stumbled into 2013 and continues to battle patent expirations and pipeline problems. Is Merck still a solid dividend play, or should investors be looking elsewhere? In a new premium research report on Merck, the Fool tackles all of the company's moving parts, its major market opportunities, and reasons both to buy and to sell. To find out more, click here to claim your copy today.
The article Merck Props the Dow Up originally appeared on Fool.com.Dan Dzombakcan be found on Twitter @DanDzombakor on his Facebook page,DanDzombak. He has no position in any stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.
Copyright © 1995 - 2013 The Motley Fool, LLC. All rights reserved. The Motley Fool has a disclosure policy.